Skip to content

Your must-see guide to RSNA 2025

Explore
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
featured-image

Press Release

RapidAI Receives First and Only FDA 510(k) Clearance of Non-Contrast CT Imaging Product to Accelerate Acute Stroke Triage

Part of RapidAI’s industry-leading stroke solution, Rapid NCCT Stroke supports faster treatment and transfer decisions while driving greater equity of care San Mateo, Calif. — April 18, 2023 — RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA 510(k) clearance for Rapid NCCT Stroke – a major addition to the RapidAI suite of non-contrast based solutions for stroke and trauma care, and the first and only FDA cleared medical device to detect suspected intracranial hemorrhage (ICH) and large vessel occlusion (LVO) from value-based CT imaging.
featured-image

Press Release

The Brain Aneurysm Foundation (BAF) Welcomes RapidAI’s Carolina Maier, PhD to Board of Directors

Maier brings decades of expertise in aneurysm research to the esteemed Board of Directors Boston, MA and San Mateo, CA.— March 23, 2023 – The Brain Aneurysm Foundation (BAF), the leading global research and advocacy organization committed to improving treatment and care for brain aneurysms, today announced the addition of Carolina Maier, PhD, Vice President of Clinical Affairs at RapidAI, the global leader in using AI to combat vascular and neurovascular conditions, to the Board of Directors.
featured-image

Press Release

RapidAI Enhances Pulmonary Embolism Care Solution with FDA 510(k) Clearance for Rapid RV/LV

Integrated with the Rapid PE solution, Rapid RV/LV further accelerates time to triage and diagnose pulmonary embolism patients with right heart strain SAN MATEO, CALIF. – February 22, 2023 – RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA 510(k) clearance for Rapid RV/LV, the newest addition to the Rapid PE solution. The tool empowers physicians to quickly assess the ratio between the right ventricle (RV) and the left ventricle (LV), a key indicator of pulmonary embolism (PE) severity. Automating this process will enable care teams to more quickly prioritize patients and accelerate decision making.
featured-image

Press Release

Rapid ICH Receives New FDA Clearance with Highest Sensitivity and Specificity on the Market

RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA 510(k) clearance for the latest release of Rapid ICH. New version of ICH reduces notification fatigue with a near perfect false positive rejection rate; and allows medical teams to make faster decisions for improved hemorrhage management
featured-image

Press Release

RapidAI Applauded by Frost & Sullivan for Delivering Quality Care Quickly and Securely With Its RapidAI Platform

RapidAI Applauded by Frost & Sullivan for Delivering Quality Care Quickly and Securely With Its RapidAI Platform SAN ANTONIO, TX. – September 12, 2022 – Frost & Sullivan recently analyzed the artificial intelligence (AI) algorithms for the stroke market, and, based on its assessment results, recognizes RapidAI with the 2022 Global Technology Innovation Leadership Award. The company is a leading provider of advanced imaging for stroke. It is a pioneer in AI-based treatment for vascular and neurovascular conditions and offers innovative solutions for more stroke diagnosis modalities than any other company in the space. RapidAI’s world-class subject matter experts developed advanced cerebrovascular imaging and workflow solutions over the last decade. The company refined its holistic approach to care for life-threatening neurovascular and vascular conditions, continuously building its comprehensive software platform to bridge the care gaps.
featured-image

Press Release

RapidAI Receives FDA Clearance for Rapid Hyperdensity

RapidAI announced it has received FDA clearance for Rapid Hyperdensity, the newest addition to the RapidAI platform San Mateo, Calif. — July 21 , 2022 — RapidAI , the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA clearance for Rapid Hyperdensity , the newest addition to the RapidAI platform. The tool empowers physicians to quickly assess the severity of injury in patients with acute neuro conditions such as traumatic brain injury and brain hemorrhages – allowing for better and faster patient care decisions. Powered by AI, Rapid Hyperdensity uses non-contrast CT scans to quickly assess the volume of hyperdense tissue in the brain to help physicians identify the extent of an intracerebral hemorrhage which is crucial for patient treatment decisions. For hospitals and mobile stroke units on the front lines of patient assessment, Rapid Hyperdensity provides additional contextual data to help physicians make more informed triage and transfer decisions–getting patients to the right place more efficiently. “Rapid Hyperdensity helps physicians make the first of many critical decisions involved in head trauma and hemorrhagic stroke protocol. As the only comprehensive neurovascular decision support platform to offer this functionality, RapidAI aims to alleviate the enormous pressure of determining the best next course of action , ” said Karim Karti, CEO of RapidAI. “This FDA clearance is a symbol of RapidAI’s ongoing commitment to push the boundaries of neurovascular care, while designing every product with physicians first in mind.” The key benefits of Rapid Hyperdensity include: Automated detection of intracranial hyperdensities >1ml Quick identification of hyperdense volumes to improve hemorrhage management Fast results that can be viewed via the Rapid mobile app, PACS/Workstation, or email "As a neurosurgeon who treats many patients with intracranial hemorrhage (ICH), I am very excited for the recently approved Rapid Hyperdensity product that builds on the well-established RapidAI stroke platform,” said Dr. Alejandro M. Spiotta, director of the Neuroendovascular Surgery Division at the Medical University of South Carolina. “Detection of ICH via AI can save lives by helping to speed up diagnosis and accelerate transfer to the best physician and hospital that can take care of the patient. With the addition of automatic hyperdense volume measurement, physicians can more easily track volume over time and help quickly identify which patients may require an intervention. This is an exciting time for those of us treating ICH." To learn more about how RapidAI is transforming stroke care, please visit: https://www.rapidai.com/stroke About RapidAI RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. Empowering physicians to make faster decisions for better patient outcomes, RapidAI is leading the next evolution of clinical decision-making and patient workflow. Based on intelligence gained from over 5 million scans in more than 2,000 hospitals in over 60 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible. RapidAI – where AI meets patient care.
featured-image

Press Release

RapidAI Receives FDA 510(k) Clearance for Pulmonary Embolism Triage & Notification

RapidAI announced that it has received FDA 510(k) clearance for its Rapid PE Triage & Notification product for fast identification and communication of suspected central pulmonary embolism. San Mateo, Calif. — May 24 , 2022 — RapidAI , the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, announced today that it has received FDA 510(k) clearance for its Rapid PE Triage & Notification product for fast identification and communication of suspected central pulmonary embolism — further strengthening RapidAI’s industry-leading clinical AI platform. New research shows that death rates for pulmonary embolism have been on the rise over the last decade , with the biggest increase among people under 65. For those who experience and survive a PE incident, one-third will have a recurrence within 10 years . Increasing access to clinically validated technology will be key to helping hospitals more efficiently coordinate care, make accurate diagnoses in a timely manner, and get PE patients to treatment faster, leading to better outcomes. “Building on our expertise in stroke, we’re confident this technology will help modernize PE care and meaningfully improve patient outcomes,” said Karim Karti, CEO of RapidAI. “Our goal is to build solutions that address the specific challenges associated with treating various conditions, as well as the communication and workflow issues faced by hospitals globally. From stroke to aneurysm to PE, we’re proud of how much RapidAI has grown and are excited to continue to redefine the patient care journey.” Rapid PE Triage & Notification, in conjunction with Rapid Workflow for PE , will enable care teams to more easily manage the entire patient care journey, from the moment a suspected PE patient is identified to diagnosis and through treatment. By automatically identifying a suspected pulmonary embolism and delivering real-time notifications to physicians, patients can be triaged faster and care teams aligned more quickly, reducing overall time to treatment. “I’m excited to see first-hand how artificial intelligence will transform the way we triage and manage PE, a historically complicated process involving a diverse care team,” said Dr. Jimmy Kerrigan, an Interventional Cardiologist at Ascension St. Thomas Heart. “After seeing what RapidAI technology has done for stroke, I’m optimistic about its potential to optimize our care for patients and to hopefully improve patient outcomes.” Join us at SIR’s 2022 Annual Scientific Meeting , Booth #346, to learn more about RapidAI clinically-validated solutions, and see a product demonstration of Rapid PE. About RapidAI RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. Empowering physicians to make faster decisions for better patient outcomes, RapidAI is leading the next evolution of clinical decision-making and patient workflow. Based on intelligence gained from over 5 million scans in more than 2,000 hospitals in over 60 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible. RapidAI – where AI meets patient care.
featured-image

Press Release

RapidAI Announces Amit Phadnis as New Chief Innovation and Technology Officer

Former GE Healthcare Chief Digital Officer joins group of new leaders spearheading RapidAI’s product innovation; advancing patient care for Pulmonary Embolism, Aneurysm and Stroke globally San Mateo, Calif. — April 6, 2022 — RapidAI , the global leader in neurovascular and vascular imaging driving the next evolution of clinical decision making and patient workflow, today announced Amit Phadnis, former GE Officer and Chief Digital Officer of GE Healthcare, as the company’s new Chief Innovation and Technology Officer. “We are thrilled to have Amit join us at RapidAI as we continue to advance our platform and suite of products to provide better care for patients around the world,” said Karim Karti, CEO of RapidAI. “His vast experience in technology, artificial intelligence, and clinical imaging will serve the team well as we deliver the future of clinical technology for life-threatening diseases.” Amit joins RapidAI with 30 years of experience in leading global product teams. In his role at GE, Amit was responsible for driving the company’s digital and AI strategy, as well as GE Healthcare’s complete digital portfolio, including enterprise imaging solutions, Clinical Command Centers and consulting solutions. With his global digital team, Amit enabled GE’s vision for precision health by creating the industry-leading Edison platform and its cloud, edge, device software infrastructure, data strategy, SaaS enablement, artificial intelligence, and analytics capabilities. Prior to GE, Amit was with Cisco Systems, where he was the India Site Leader and Senior Vice President of Engineering for the Core Software Group, leading product development activities across the routing, switching and wireless areas. Amit has also previously held leadership roles at Motorola, Tata Elxsi, Silicon Automation Systems, and C-DOT. He earned his master’s degree in electronics and communication from the Indian Institute of Science. “I look forward to working with the talented technologists, engineers, and sales leaders at RapidAI, to advance our artificial intelligence platform and meaningfully improve physician workflow and patient outcomes,” said Phadnis. “I was drawn to RapidAI because of its unique suite of products and incredible leadership in the industry. I am grateful for the opportunity to bring my experience to the team and continue to develop technology that pushes the boundaries of care.” As the Chief Innovation and Technology Officer at RapidAI, Amit will oversee the R&D, Engineering and Technology organizations, driving the advancement of the RapidAI comprehensive AI and Workflow Platform for neurovascular and vascular disease care and beyond. RapidAI’s platform leverages AI to create enhanced, high-quality images from NCCT, CTA, CTP and MRI diffusion and perfusion data, which are available to physicians on web and mobile devices. The technology helps physicians make expedient diagnoses and treatment and transfer decisions, and allows for more streamlined communication and coordination of the patient journey. Though its foundations are in the treatment of stroke, RapidAI’s technology has been evolved to apply to several other disease states, with continued advancements to come in the future. In August, RapidAI reached more than 4 million scans on its platform – the most clinically advanced in the industry.
featured-image

Press Release

RapidAI Announces Karim Karti as New CEO

Former GE Healthcare Imaging and iRhythm leader joins pioneers in clinical decision making and patient care coordination San Mateo, Calif. — January 31, 2022 — RapidAI, the global leader in neurovascular and vascular imaging driving the next evolution of clinical decision making and patient workflow, today announced Karim Karti, former President and CEO of GE Healthcare Imaging, as the company’s Chief Executive Officer (CEO). “Karim’s tremendous global experience in healthcare technology and digital health makes him an ideal fit for RapidAI. He has a proven track record in driving commercial success, product expansion and global scale. RapidAI is at a very exciting time in our history as we are scaling the company and substantially expanding our product and global footprint. I’m confident Karim will help ensure our continued growth as the worldwide leader in clinical decision making and patient workflow technology,” said Dr. Greg Albers, Chairman and Co-founder of RapidAI. “RapidAI’s unparalleled clinical validation combined with Karim’s thoughtful approach to business growth will ensure that we continue to support hospitals, physicians, and millions of patients as we advance the treatment of neurovascular diseases, as well as other critical medical disorders.” Karim Karti comes to RapidAI with more than 25 years of experience in the medical technology industry and a demonstrated ability of growing companies and helping them achieve key milestones. He served as Chief Operating Officer at iRhythm Technologies, a cardiac monitoring and AI digital health company. During his tenure, Karim doubled iRhythm’s revenues in 18 months while successfully launching several new breakthrough AI products. Karim also serves as Chairman of the Board for MedTech Acquisition Corporation and is a Director of Rockley Photonics. Notably, Karim spent over 22 years at General Electric, where he worked as President and CEO of GE Healthcare Korea, before being tapped as President and CEO of Emerging Markets, and subsequently Global Chief Marketing Officer for the entire $20B GE Healthcare division. Karim was appointed President and CEO of GE Healthcare Imaging in 2016 and led it to become one of the fastest growing businesses at GE in 2017. In this position, Karim drove significant growth, profitability, and innovation, spearheading a new digital platform and investments in AI-based imaging. “I am proud and humbled to join Dr. Albers, Dr. Roland Bammer, and the whole team at RapidAI in their mission to improve the diagnosis and treatment of life-threatening conditions. As trailblazers in the space, RapidAI has helped to shape the way we diagnose and treat neurovascular and vascular disease and made a meaningful impact in the lives of people around the world,” said Karti. “I look forward to bringing my own experience in imaging, artificial intelligence and digital health to help push the boundaries of clinical technology and patient care even further and continue to save lives. RapidAI has pioneered the field with five key randomized clinical trials, all published in the New England Journal of Medicine, that set a new standard for stroke treatment worldwide and showed the superior approach of the RapidAI solution. RapidAI is the undisputed leader with a presence in over 2000 hospitals and 60 countries, a testament to the value of RapidAI for patients, physicians, hospitals and health systems.” Karim’s leadership philosophy is rooted in open communication and nurturing talent and diversity. He believes in a leadership approach that combines full transparency, teamwork and collaboration with a passion for advancing clinical innovation and helping patients around the world. Karim has a MSc in engineering from Ecole Centrale de Lyon and completed the entrepreneurship program of Ecole Superieure de Commerce de Lyon. He lives with his wife and two daughters in the Bay Area. "I have been extremely impressed by the depth of Karim’s experience, leadership and passion for innovation. I look forward to working with him as we expand the breadth and depth of our product portfolio," said Dr. Roland Bammer, CTO and Co-founder of RapidAI. RapidAI’s platform leverages AI to create enhanced, high-quality images from NCCT, CTA, CTP and MRI diffusion and perfusion data, which are available to physicians through PACS, email, and the Rapid mobile and web apps. The technology helps physicians make expedient diagnoses, treatment and transfer decisions, and allows for more streamlined communication and coordination of the patient journey. Though its foundations are in the treatment of stroke, RapidAI technology has evolved to cover aneurysm and pulmonary embolism, with continued advancements to come. RapidAI has processed more than 4 million scans on its platform – the most clinically advanced in the industry.
1 2 3 4 5